Engineering Immunity – what did we learn from ASGCT20?
ASGCT Virtual: We are thoroughly enjoying the “live” annual meeting of the American Society of Gene and Cell Therapy (ASGCT).
Unlike other virtual meetings that have recorded presentations, ASGCT are running a live format, with presenters giving their talks in real-time from wherever in the world they may be. By and large this has worked well, and it definitely felt as though you were at the meeting.
We are also enjoying the ePoster hall, and in particular, the short audio tour that many presenters have made to take you through their poster. Obviously, it’s not a substitute for in-person contact, but who would want to be in a crowded poster hall or meeting room in these uncertain times with the potential for the coronavirus lurking about?
Earlier today we “attended” a virtual ASGCT20 scientific session with oral presentations organized by the American Society for Transplantation and Cellular Therapy (ASTCT) on Engineering Immunity.
Four speakers focused on CAR T cell therapy in non-B cell malignancies – what did we learn? It turns out the answer was quite a bit!
To find out more about our oncology analysis and get a heads up on insights and commentary emerging from the ASGCT meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
